10.22376/ijpbs.2019.10.1.p1-12 Volume 1 Issue 2 2010 (April - June) An open, randomized, comparative, Phase II clinical trial on 20 patients with Constipation – Predominant Irritable Bowel Syndrome (IBS–C) was conducted for 6 weeks for evaluating safety, tolerability and efficacy of Oxy Powder® (OP) compared with Dulcolax (DX) tablets. The results indicated that complete cure was obtained in 30.8% and improvement in 69.2% patients treated with OP. In case of DX, improvement was seen in 71.4% patients and failure in 28.6% patients. There was no failure in case of OP indicating that efficacy of OP in treating IBS–C was significantly higher (p Jogender K. Lalla,Deven V. Parmar,Meena U. Shah,Edward III Group GHC Oxy Powder®, Dietary supplement vs. Dulcolax– IBS–C Clinical Trial – Rome ll Criteria – ICH E6 GCP Guidelines– WMA Declaration of Helsinki – Drug Rules Schedule Y (Amendment 2005) -